Poor targeting of therapeutics leading to severe adverse effects on normal tissues is
considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug …

Photodynamic therapy (PDT) has aroused great research interest in recent years owing to its
high spatiotemporal selectivity, minimal invasiveness, and low systemic toxicity. However …

Cancer immunotherapy has made tremendous clinical progress in advanced-stage
malignancies. However, patients with various tumors exhibit a low response rate to …

Glutathione (GSH), the main redox buffer, has long been recognized as a pivotal modulator
of tumor initiation, progression and metastasis. It is also implicated in the resistance of …

Innovative anticancer therapies based on the activation of the immune system offer promise
in the battle against cancers resistant to traditional treatments. Examples of such therapeutic …

Immunotherapy has emerged as a promising cancer treatment modality. Despite the rapid
progress in cancer immunotherapy, the therapeutic efficiency and clinical translation of …

The past decade has witnessed major breakthroughs in cancer immunotherapy. This
development has been largely motivated by cancer cell evasion of immunological control …

An ideal cancer treatment should not only destroy primary tumors but also improve the
immunogenicity of the tumor microenvironment to achieve a satisfactory anti‐tumor immune …

Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Iron-based nanoparticles have attracted much attention because of their ability to induce
ferroptosis via a catalyzing Fenton reaction and to further potentiate immunotherapy …